Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Enhanced drug targeting by attachment of an anti alpha v integrin antibody to doxorubicin loaded human serum albumin nanoparticles

: Wagner, S.; Rothweiler, F.; Anhorn, M.G.; Sauer, D.; Riemann, I.; Weiss, E.C.; Katsen-Globa, A.; Michaelis, M.; Cinatl, J.; Schwartz, D.; Kreuter, J.; Briesen, H. von; Langer, K.


Biomaterials 31 (2010), No.8, pp.2388-2398
ISSN: 0142-9612
ISSN: 1878-5905
Journal Article
Fraunhofer IBMT ()

Specific transport of anti-cancer drugs into tumor cells may result in increased therapeutic efficacy and decreased adverse events. Expression of alpha v beta 3 integrin is enhanced in various types of cancer and monoclonal antibodies (mAbs) directed against alpha v beta 3 integrins hold promise for anti-cancer therapy. DI17E6 is a monoclonal antibody directed against alpha v integrins that inhibits growth of melanomas in vitro and in vivo and inhibits angiogenesis due to interference with alpha v beta 3 integrins. Here, DI17E6 was covalently coupled to human serum albumin nanoparticles. Resulting nanoparticles specifically targeted alpha v beta 3 integrin positive melanoma cells. Moreover, doxorubicin loaded DI17E6 nanoparticles showed increased cytotoxic activity in alpha v beta 3-positive melanoma cells than the free drug. Therefore, DI17E6-coupled human serum albumin nanoparticles represent a potential delivery system for targeted drug transport into alpha v beta 3-positive cells.